argenx (NASDAQ:ARGX) Price Target Raised to $500.00 at Stifel Nicolaus

argenx (NASDAQ:ARGX) had its target price boosted by Stifel Nicolaus from $485.00 to $500.00 in a research report released on Monday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

A number of other equities analysts have also recently weighed in on ARGX. Wells Fargo & Company boosted their price target on argenx from $478.00 to $542.00 and gave the stock an overweight rating in a report on Monday. JMP Securities cut their target price on argenx from $471.00 to $468.00 and set a market outperform rating on the stock in a research report on Friday, May 10th. Truist Financial boosted their price target on argenx from $370.00 to $440.00 and gave the company a buy rating in a research report on Tuesday, March 5th. Scotiabank raised their price objective on argenx from $402.00 to $408.00 and gave the stock a sector perform rating in a report on Tuesday, March 26th. Finally, HC Wainwright reiterated a buy rating and set a $448.00 target price on shares of argenx in a report on Monday. Five investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $525.42.

argenx Stock Down 0.2 %

Shares of ARGX opened at $444.94 on Monday. The company has a market capitalization of $26.44 billion, a PE ratio of -78.61 and a beta of 0.65. argenx has a 52-week low of $327.73 and a 52-week high of $550.76. The company has a 50-day simple moving average of $381.58 and a 200-day simple moving average of $387.30.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million during the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same period in the previous year, the business earned ($0.52) earnings per share. On average, research analysts anticipate that argenx will post -2.89 EPS for the current year.

Institutional Trading of argenx

Hedge funds and other institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD increased its holdings in argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after purchasing an additional 1,830,651 shares during the last quarter. Artisan Partners Limited Partnership increased its position in shares of argenx by 12.2% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock worth $1,207,666,000 after purchasing an additional 346,178 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of argenx by 24.8% in the 1st quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after purchasing an additional 439,889 shares during the last quarter. Capital World Investors raised its stake in shares of argenx by 37.0% in the 4th quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after purchasing an additional 530,181 shares in the last quarter. Finally, Avoro Capital Advisors LLC lifted its position in shares of argenx by 0.3% during the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after purchasing an additional 3,900 shares during the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.